DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06271200

RecruitingPhase NA

Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Effects of Intensive Lifestyle Interventions (ILI) on Weight Loss and Cardiometabolic Risks in Obese Adults With Metabolic Syndrome: A Randomized Clinical Trial

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

200

estimated

Study population

Metabolic syndrome, Obesity / overweight

Key I/E criterion

•BMI 27-45

Primary endpoint

•The metabolic syndrome severity score (Z score) after reduction > 5% body weight

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06271200
Org study IDMG-113-GP-03

Timeline

Milestones

Study first posted2024-02-21actual
Study start2024-03-14actual
Last update posted2026-04-08actual
Primary completion2027-10-10estimated
Study completion2027-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Metabolic syndromeObesity / overweight

Eligibility

Who can enroll

Minimum age20 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Men or women aged from ≥ 20 years to 65 years
•BMI 27.0 to 45.0 kg/m2 with metabolic syndrome by IDF definition

Exclusion criteria

•History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis
•Diagnosis of type 1 or type 2 diabetes and regular taking oral or injection hypoglycemic therapy
•History of malignant tumors with active managements.
•History of medullary thyroid carcinoma or diagnosis of multiple endocrine neoplasia syndrome type 2 (MEN 2)
•Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2)
•History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months History of severe gastrointestinal diseases or gastrointestinal surgery in the past 6 months
•History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity without regular managements.
•History of hypersensitivity to semaglutide or any component of RYBELSUS®, or history of severe hypersensitivity reactions to Forxiga, such as anaphylaxis or angioedema.
•Taking medications affecting weight or energy intake/energy expenditure in the last 3 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician
•Currently participating in weight loss programs or weight change in the past 3 months (>5% current body weight)
•Women who are pregnant or plan to become pregnant
•Patients who cannot be followed for 3 years (due to a health situation or migration)
•Patients who are unwilling or unable to give informed consent

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

Change in the metabolic syndrome severity score (Z score) after reduction > 5% body weight from baseline to 24 weeks

Time frame:24 weeks

change from baseline, improvement

Publications (24)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.